
Progyny (PGNY) Stock Forecast & Price Target
Progyny (PGNY) Analyst Ratings
Bulls say
Progyny is expected to continue its strong performance, with solid quarterly results and a 2026 sales season showing signs of achieving or exceeding its 1 million new covered lives target. Additionally, the implementation of California's IVF mandate in 2026 is expected to provide a significant revenue opportunity for Progyny, potentially adding $15B in TAM for the company. With a strong track record and expanding market opportunities, Progyny may continue to outperform and achieve its goal of becoming a leading fertility benefits provider.
Bears say
Progyny is facing several challenges in the short and long term that could negatively impact the company's financial performance. These challenges include potential economic uncertainty impacting purchasing decisions and member utilization, a competitive marketplace with traditional health plan carriers and private tech-enabled health companies, and potential changes in government regulations. Furthermore, the company's current valuation at only 7x NTM EV/adjusted EBITDA is a discount compared to its peers with similar growth and margins.
This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares